A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.

Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...

Investing.com -- Kairos Pharma Ltd (NYSE: KAPA) stock surged 165% after the clinical-stage biopharmaceutical company reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 ...

Find the latest Revenue Earnings Per Share data for Kairos Pharma, Ltd. Common Stock (KAPA) at Nasdaq.com.

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...

--Kairos Pharma, Ltd. today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. The dual listing on Upstream is designed to ...

Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...